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A B S T R A C T   
Background: Schizophrenia is associated with elevated levels of circulating C-reactive protein (CRP) and other 
inflammatory markers, but it is unclear whether these associations extend to psychotic symptoms occurring in 
adolescence in the general population. A symptom-based approach may provide important clues for apparent 
trans-diagnostic effect of inflammation, which is also associated with depression and other psychiatric disorders. 
Methods: Based on data from 2421 participants from the Avon Longitudinal Study of Parents and Children birth 
cohort, we examined associations of serum CRP levels assessed around age 16 with ten positive and ten negative 
symptoms of psychosis assessed using questionnaires around age 17, using both individual symptoms and 
symptom dimension scores as outcomes. Regression models were adjusted for sex, body mass index, depressive 
symptoms, substance use, and other potential confounders. 
Results: Most prevalent positive symptoms were paranoid ideation (4.8%), visual (4.3%) and auditory (3.5%) 
hallucinations. Negative symptoms were more strongly correlated with concurrent depressive symptoms 
(r=0.51; P < 0.001) than positive symptoms (rpb=0.19; P < 0.001). The associations of CRP with positive and 
negative symptom dimension scores were similar. At individual symptom level, after adjusting for potential 
confounders including depressive symptoms, CRP was associated with auditory hallucinations (adjusted OR =
2.22; 95% CI, 1.04–4.76) and anhedonia (adjusted OR = 1.13; 95% CI, 1.02–1.26). 
Conclusions: Inflammation is associated with sub-clinical psychotic symptoms in young people in general pop-
ulation. Association of CRP with symptoms commonly shared between mood and psychotic disorders, such as 
auditory hallucinations and anhedonia, could be one explanation for the apparent trans-diagnostic effect of 
inflammation.   
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1. Introduction 
Low-grade systemic inflammation as reflected by increased concen-
trations of acute phase proteins, such as C-reactive protein (CRP), and 
inflammatory cytokines, such as interleukin 6 (IL-6), in peripheral blood 
has been implicated in pathogenesis of a number of psychiatric disorders 
including schizophrenia and related psychoses (Khandaker et al., 2015; 
Miller et al., 2011), depression (Dantzer et al., 2008; Miller et al., 2009), 
anxiety (Wohleb et al., 2014), post-traumatic stress disorder (Eraly et al., 
2014), autism (Brown et al., 2014), Alzheimer’s disease and other de-
mentias (Schmidt et al., 2002). However, possible reasons for this 
apparent trans-diagnostic association of inflammation are unknown. 
Most human studies are based on categorical diagnosis of illness, but a 
symptom-based approach may help to elucidate why association be-
tween inflammation and psychiatric disorders transcends traditional 
diagnostic boundaries. It is possible that inflammation contributes to 
pathogenesis of symptoms that are shared between disorders. 
There is a rich literature linking infection and elevated levels of in-
flammatory markers with the risk of schizophrenia (Benros et al., 2011; 
Brown and Derkits, 2010; Buka et al., 2001; Dickerson et al., 2003; 
Khandaker et al., 2012, 2013, 2015; Mortensen et al., 2007; Prasad 
et al., 2012). Meta-analysis of cross-sectional studies confirm that con-
centrations of circulating CRP, IL-6 and other inflammatory markers are 
elevated during an acute psychotic episode (Miller et al., 2011, 2013; 
Potvin et al., 2008; Upthegrove et al., 2014), which tend to normalize 
after recovery but continue to be elevated in treatment resistant patients 
(Goldsmith et al., 2016). Longitudinal studies reporting an association 
between higher blood IL-6, CRP, erythrocyte sedimentation rate (ESR) in 
childhood/adolescence and increased risks of psychotic symptoms 
(Khandaker et al., 2014) or diagnosis of schizophrenia (Kappelmann 
et al., 2019; Metcalf et al., 2017) subsequently in adulthood indicate that 
inflammation may play a role in causing psychosis rather than simply 
being a consequence of illness. 
Psychotic disorders consist of diverse symptoms, some of which are 
shared by other disorders. For instance, auditory hallucinations can 
occur in psychosis, depression and anxiety disorders (APA, 2013). 
Anhedonia is both an important negative symptom for psychosis and a 
core feature of depression (APA, 2013). However, studies examining 
association between inflammation and specific symptoms of psychosis 
are limited. Existing studies have reported an association of CRP with 
negative symptoms (Boozalis et al., 2017), general psychopathology 
(Fan et al., 2007) and cognitive dysfunction (Dickerson et al., 2007; 
Johnsen et al., 2016) in patients with psychosis. Psychotic symptoms 
reported by adolescents and adults in general population thought to 
exist in a continuum with clinical psychosis (van Os et al., 2009), and are 
associated with a range of psychotic and non-psychotic disorders 
cross-sectionally and longitudinally (Kelleher et al., 2012b; McGrath 
et al., 2016; Poulton et al., 2000; Zammit et al., 2013). However, to our 
knowledge no population-based studies have examined the association 
between CRP and positive and negative symptoms of psychosis in a 
general population-based sample. 
We present a longitudinal study of serum CRP concentration assessed 
around age 16 years and subsequent self-reported positive and negative 
symptoms of psychosis assessed around age 17 years in the Avon Lon-
gitudinal Study of Parents and Children (ALSPAC), a general population- 
representative birth cohort from the United Kingdom. We hypothesised 
that elevated CRP levels would be associated with specific psychotic 
symptoms commonly shared by other disorders. We used individual 
symptoms and factors scores for positive and negative symptom di-
mensions as our outcomes. Mood symptoms often co-occur with psy-
chotic symptoms (Stochl et al., 2015) and are associated with elevated 
inflammatory markers (Howren et al., 2009), as are smoking, alcohol, 
cannabis and other drug use. We have adjusted for these important 
confounders, and carried out sensitivity analyses after excluding par-
ticipants who reported positive symptoms in the context of drugs, 
physical illness or sleep. 
2. Methods 
2.1. Sample 
The ALSPAC birth cohort initially recruited 14541 pregnant women 
resident in study catchment areas in Southwest England who had ex-
pected delivery dates between April 1, 1991 and December 31, 1992, 
resulting in 14062 live births. Additional children and parents were 
subsequently recruited into the cohort. Since age 7 years, the children 
attended annual clinical assessments during which they participated in 
various face-to-face interviews and physical tests. Detailed information 
about the ALSPAC cohort can be found on the study website (htt 
p://www.bristol.ac.uk/alspac), and the sample characteristics and 
methodology have been described previously (Boyd et al., 2013; Fraser 
et al., 2013). For information on all available ALSPAC data, see the fully 
searchable data dictionary (http://www.bris.ac.uk/alspac/researcher 
s/data-access/data-dictionary). The risk set for the current study 
comprised 3488 participants with data on serum CRP levels around age 
16 years. All analysis was based on maximum available sample (see 
Tables). The analysis for association of CRP with positive and negative 
symptoms comprised 2421 and 2419 participants, respectively. Ethical 
approval for the study was obtained from the ALSPAC Ethics and Law 
Committee and the Local Research Ethics Committees. 
2.2. Measurement of high sensitivity CRP 
Blood samples were collected from participants who gave consent for 
venepuncture during clinical assessment at average age 15.5 years (SD 
= 0.35). Participants fasted overnight before attending the clinic if seen 
in the morning, or at least for 6 h if seen in the afternoon. Blood samples 
were immediately spun, frozen and stored at − 80 ◦C, which were ana-
lysed within 3–9 months of blood sampling with no freeze-thaw cycles in 
between. High sensitivity CRP (hsCRP) was measured by automated 
particle-enhanced immunoturbidimetric assay (Roche UK, Welwyn 
Garden City, UK). No other inflammatory makers were measured. 
Among all 3488 participants, serum CRP level ranged from 0.07 to 
72.55 mg/L; 62 participants (1.77%) had CRP levels ≥10 mg/L. Based 
on the American Heart Association and the US Centers for Disease 
Control and Prevention guidelines on the use of hsCRP levels in epide-
miological studies (Pearson et al., 2003), hsCRP was coded as a cate-
gorical variable: <1 mg/L = “low”; 1–3 mg/L = “medium”; >3 mg/L =
“high”. hsCRP was also used as a continuous variable. 
2.3. Assessment of positive symptoms 
Participants completed a questionnaire at average age 16.6 years 
(SD = 0.23), which included 10 questions about positive symptoms of 
psychosis asking whether they had experienced these symptoms at least 
once since 15th birthday (eTable 1). The questionnaire was modelled on 
the psychotic-like symptoms interview (PLIKSi) which was administered 
in the same cohort at age 12 years (Zammit et al., 2013). The symptoms 
elicited can be classed under three major domains: hallucinations 
(auditory; visual); delusions (paranoid beliefs to have been followed/s-
pied on; belief someone else has read their thoughts; feeling that they 
were someone really special or had special powers, i.e., grandiosity; 
belief to have received messages from television/radio, i.e., ideas of 
reference; feeling of being under the control of a special power, i.e., 
passivity); thought interference (thought insertion, withdrawal, and 
broadcasting). For each question, participants were given three options: 
definitely yes; may be; no, never. Cases were defined as participants 
reporting to have definitely experienced a psychotic symptom. The other 
two groups (yes, may be and no, never) were merged and used as con-
trol. This is because due to lack of cross-questioning, as in an interview, 
we are less confident whether those reporting “may be” in the ques-
tionnaire indeed experienced a positive symptom. 
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2.4. Assessment of negative symptoms 
Negative symptoms were assessed using a questionnaire, which 
included 10 questions based on items from the validated Community 
Assessment of Psychic Experiences (CAPE) questionnaire (Stefanis et al., 
2002), administered at the same time as the questionnaire for positive 
symptoms. These covered difficulties with interest, motivation, 
emotional reactivity, pleasure, and sociability. Participants rated each 
item on a 4-point scale (0 = never; 1 = sometimes; 2 = often; and 3 =
always) (eTable 2). We were interested in symptoms that were more 
frequent, so perhaps clinically relevant. Therefore, we recoded each 
item into a binary variable by coding ‘often’ and ‘always’ as 1 =
symptom present; ‘never’ and ‘sometimes’ as 0 = symptom absent. A 
total score was constructed by summing ten items (range 0–10). 
According to empirical research (Messinger et al., 2011) and the US 
National Institute of Mental Health expert consensus statement (Kirk-
patrick et al., 2006) there are five specific sub-types of negative symp-
toms: blunted affect, alogia, anhedonia, asociality, and avolition. These 
can be grouped into two major domains: expressive deficits (blunted 
affect, alogia) and avolition (anhedonia, asociality, avolition). We 
created a score for each symptom sub-type by summing individual 
questions, although alogia, anhedonia and asociality were measure by 
single questions (eFig. 1). We also created two major domain scores; 
total score for expressive deficits ranged from 0 to 3, and that for avo-
lition ranged from 0 to 7. 
2.5. Assessment of potential confounders 
Ethnicity and father’s occupation were recorded during pregnancy; 
sex was recorded at birth; body mass index (BMI) was recorded around 
blood collection for CRP assay; age (in months) was recorded at the time 
of assessment of psychotic symptoms. Father’s occupation was coded in 
six categories as per the UK Office of National Statistics classification 
system: I, II, III non-manual, III manual, IV, V (in descending order with 
professionals and higher managerial workers representing social class I). 
Depressive symptoms were assessed at the time of assessment of psy-
chotic symptoms using the validated short mood and feelings ques-
tionnaire (SMFQ) (Angold et al., 1995). The SMFQ comprises 13 items 
covering core symptoms of depression and anxiety experienced in past 
two weeks. Each item is scored zero (not true), one (sometimes true) or 
two (true) giving a total score of 0–26. 
Smoking, alcohol, cannabis and other drug use were recorded using a 
questionnaire administered alongside assessment of psychotic symp-
toms. Number of cigarettes/roll ups smoked per day was coded as cat-
egorical variable: do not smoke; 1–5; 6–10; >10 cigarettes. Frequency of 
alcohol use was coded as never; monthly or less frequently; two to four 
times a month; twice a week or more frequently. The amount of cannabis 
used in past three months was coded as nil; <8th of an ounce; >8th of an 
ounce. Use of any other drugs since 15th birthday was coded as a single 
binary variable. Other drugs included inhaling/sniffing gas, solvent, 
aerosol, glue/poppers (alkyl nitrites); stimulants (amphetamine, 
MDMA, cocaine/crack cocaine), hallucinogens (LSD, magic mushroom); 
heroin, ketamine, anabolic steroids. 
2.6. Statistical analysis 
2.6.1. Baseline comparisons 
Distributions of covariates were compared among groups with low, 
medium and high levels of CRP at baseline using one-way analysis of 
variance for continuous variables (e.g., age) and Chi-squared test for 
categorical variables (e.g., sex). We tested correlation of total negative 
symptom score with any positive symptoms (binary) using point bi- 
serial correlation, and with total SMFQ score using Spearman’s 
correlation. 
2.6.2. Association of CRP with positive and negative symptom dimension 
scores 
First, we carried out exploratory factor analysis (EFA) based on 10 
positive and 10 negative symptoms to test whether these symptoms 
represent one, two or three underlying factors. The two-factor solution 
representing positive and negative symptoms was chosen as optimum 
based on the interpretability of factors, and model fit indices (compar-
ative fit index (CFI), Tucker-Lewis index (TLI), and Root Mean Square 
Error of Approximation (RMSEA)) obtained using MPlus software 
(Muthén and Muthén, 1998–2011). Then, we extended the factor ana-
lytic model to test association between CRP and positive and negative 
symptom factors scores. 
2.6.3. Association between CRP and individual positive symptoms 
We used logistic regression to calculate odds ratio (OR) and 95% 
confidence intervals (CI) for common, individual symptoms (auditory 
hallucinations, visual hallucinations and paranoid belief) for partici-
pants with medium and high, compared with low, CRP levels. ORs were 
also calculated for any hallucinations, delusions and thought interfer-
ence (separately). All regression models were adjusted for age, sex, BMI, 
father’s occupation, ethnicity, total SMFQ score, smoking, alcohol, 
cannabis and other drug use. 
2.6.4. Association between CRP and individual negative symptoms 
We used logistic regression to examine association between CRP 
(continuous variable; Z-transformed) and anhedonia, asociality and 
alogia, so the ORs represent increase in risk of each symptom per SD 
increase in CRP. We used linear regression for the other negative 
symptom subtypes and two major domain scores as these were coded as 
continuous variables. Regression models were adjusted for all con-
founders mentioned above. 
2.6.5. Sensitivity analyses 
We re-examined the association between CRP and auditory halluci-
nations after excluding participants who had reported to experience any 
positive symptoms only in the context of substance use (within 24 h of 
using cannabis or other drugs), illness (fever) or sleep (falling asleep/ 
waking up). We also re-examined this association after excluding par-
ticipants who had previously been assessed to have any positive symp-
toms at age 12 years (Zammit et al., 2008) to minimize reverse causality. 
We also reassessed the main findings after excluding participants with 
CRP>10 mg/L from the sample as this may indicate current infection. 
2.6.6. Correction for multiple testing 
P-values for unadjusted ORs for specific positive/negative symptoms 
were corrected using Holm-Bonferroni method (Holm, 1979). 
3. Results 
3.1. Baseline characteristics of sample 
Around age 16 out of all 3488 participants with blood data, 263 
(7.5%) had high CRP levels (>3 mg/L). CRP associated with BMI and 
tobacco, cannabis and other drug use, but not with sociodemographic 
factors or total SMFQ score (Table 1). 
3.2. Prevalence of positive symptoms of psychosis 
Around age 17 out of total 5126 participants assessed, 682 (13.3%) 
reported at least one positive symptom (eTable 3). Paranoid beliefs of 
being followed or spied on (4.8%), visual hallucinations (4.3%) and 
auditory hallucinations (3.5%) were most common (Fig. 1). 
3.3. Relationship of negative symptoms with positive and mood symptoms 
The median (IQR) for total negative symptom score was 0 (0–2). 
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Total negative symptom score was more strongly correlated with total 
SMFQ score (Spearman’s rho=0.51; P < 0.001; N = 4981) than positive 
symptoms (rpb=0.19; P < 0.001; N = 5108). 
3.4. Association of CRP with positive and negative symptom dimension 
scores 
EFA of 10 positive and 10 negative symptoms showed that the two- 
factor model was optimum based on model fit indices, parsimony and 
interpretability (eTable 4). Two factors represented positive and nega-
tive symptom dimensions, which were correlated; r=0.44 (P < 0.05). 
The association of CRP with positive (β = 0.074; SE = 0.040; P = 0.063) 
and negative (β = 0.052; SE = 0.026; P = 0.049) symptom dimension 
scores was similar (Fig. 2). 
3.5. Association between CRP and specific positive symptoms 
High, compared with low, serum CRP levels were associated with 
auditory hallucinations after controlling for age, sex, BMI, father’s 
occupation, ethnicity, depressive symptoms, smoking, alcohol, cannabis 
and other drug use; adjusted OR = 2.22 (95% CI, 1.04–4.76) (Table 2). 
CRP was not associated with any other positive symptoms. 
3.6. Association between CRP and specific negative symptoms 
CRP was associated with anhedonia. The OR for anhedonia per SD 
increase in serum CRP levels was 1.13 (95% CI, 1.04–1.23); P=0.003. 
Evidence for this association remained after adjusting for current mood 
(P=0.007), and all potential confounders (P=0.023) (Table 3). The as-
sociation of CRP with asociality and alogia was no longer significant 
after adjusting for confounders. Out of two negative symptom domains, 
after adjusting for potential confounders CRP was associated with avo-
lition (which includes anhedonia) (regression co-efficient = 0.057; SE =
0.028; P = 0.042), but not with expressive deficit (eTable 5). 
3.7. Results for sensitivity analyses 
Evidence for association between CRP levels and auditory halluci-
nations remained after excluding participants who experienced positive 
symptoms in the context of cannabis/other drug use, illness or sleep; 
adjusted OR = 2.49 (95% CI, 1.01–6.17). Evidence for this association 
remained after excluding participants who had reported any psychotic 
symptom previously at age 12 years; adjusted OR = 4.52 (95% CI, 
1.84–11.08). Evidence for association between CRP and auditory hal-
lucinations also remained after excluding participants with CRP>10 
mg/L at baseline; adjusted OR = 2.82 (95% CI, 1.25–6.37); please see 
eTable 6. After excluding participants with CRP>10 mg/L at baseline, 
the adjusted OR for anhedonia per SD increase in CRP remained similar 
to the primary results, but the 95% CI widened and included the null; 
adjusted OR = 1.21 (95% CI, 0.80–1.84). 
3.8. Correction for multiple testing 
After Holm-Bonferroni correction, the P-values for unadjusted ORs 
for auditory hallucinations (P=0.042) and anhedonia (P=0.015) 
remained significant (eTable 7-8). 
4. Discussion 
Based on a general population-based cohort of adolescents, our 
findings indicate that inflammation is associated with auditory hallu-
cinations and anhedonia specifically out of all twenty positive and 
negative symptoms studied. Evidence for these associations persisted 
after adjustments for sex, body mass index, depressive symptoms, soci-
odemographic factors and substance use, and after correction for mul-
tiple testing. Evidence for association between CRP and auditory 
hallucinations also remained in sensitivity analyses focusing on more 
clinically relevant symptoms or excluding participants with preexisting 
symptoms. Negative symptoms were strongly correlated with depressive 
symptoms, but evidence for association between CRP and anhedonia 
Table 1 
Baseline characteristics of sample.  
Characteristic Serum CRP level at age 16 years P- 
Value3  
Low (>1 
mg/L) 
Medium 
(1–3 mg/L) 
High 
(>3 mg/ 
L)  
Total Sample, No. (%) 2685 
(77.0) 
540 (15.5) 263 (7.5) – 
Female Sex, No. (%) 1371 
(51.1) 
285 (52.8) 133 
(50.6) 
0.74 
British White Ethnicity, No. 
(%) 
2423 
(98.2) 
475 (97.3) 229 
(97.4) 
0.45 
Father’s Occupation, No. (%)    0.17 
I 342 
(15.0) 
59 (13.1) 17 (7.8) 
II 860 
(37.7) 
161 (35.9) 78 (35.9) 
III non-manual 282 
(12.4) 
51 (11.4) 26 (12.0) 
III manual 581 
(25.5) 
127 (28.3) 70 (32.3) 
IV 171 
(7.5) 
41 (9.1) 20 (9.2) 
V 41 (1.8) 10 (2.2) 6 (2.8) 
BMI around CRP assessment, 
Mean (SD)a 
21.00 
(2.94) 
23.36 
(4.54) 
23.40 
(4.89) 
<0.001 
Age at Assessment of 
Psychotic Symptoms, mean 
(SD), Months 
200 
(2.83) 
200 (2.89) 200 
(2.73) 
0.89 
Total SMFQb Score at 
Assessment of Psychotic 
Symptoms, Mean (SD) 
5.67 
(5.41) 
5.64 (5.59) 6.24 
(6.13) 
0.44 
Cigarettes smoked per day, 
No. (%)    
0.07 
Do not smoke 1685 
(88.1) 
310 (88.8) 135 
(85.4) 
1-5 cigarettes 114 
(6.0) 
13 (3.7) 8 (5.1) 
6-10 cigarettes 75 (3.9) 13 (3.7) 7 (4.4) 
>10 cigarettes 38 (2.0) 13 (3.7) 8 (5.1) 
Frequency of alcohol use, No. 
(%)    
0.66 
Never, monthly or less 
frequently 
821 
(42.9) 
158 45.3) 66 (41.8) 
Two to four times a month 790 
(41.3) 
132 (37.8) 70 (44.3) 
Twice a week or more 
frequently 
301 
(15.7) 
59 (16.9) 22 (13.9) 
Amount of cannabis used in 
past three months, No (%)    
0.01 
Nil 1626 
(85.0) 
298 (85.5) 128 
(81.0) 
<8th of an ounce 215 
(11.2) 
44 (12.6) 17 (10.8) 
>8th of an ounce 71 (3.7) 7 (2.0) 13 (8.2) 
Use of any other drug since 
15th birthday3, No. (%) 
286 
(15.7) 
47 (14.5) 34 (23.8) 0.02 
3 Other drugs included inhaling/sniffing of gas, solvent, aerosol, glue or poppers; 
use of stimulants (amphetamine, MDMA, cocaine or crack cocaine), hallucino-
gens (LSD, magic mushroom); heroin, ketamine, and anabolic steroids. 
3 For continuous variables One Way Analysis of Variance was used to compare 
mean values among groups (age and total SMFQ score at assessment of psychotic 
symptoms); For categorical variables Chi-squared test was used to compare 
proportions among groups (sex, ethnicity, father’s occupation, smoking, 
cannabis, alcohol, and other drug use). 
a BMI=Body Mass Index. 
b SMFQ=Short Mood and Feelings Questionnaire. 
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Fig. 1. Frequency of positive symptoms of psychosis around age 17 Years in the alspac birth cohort.  
Fig. 2. Structural equation model for association between CRP and positive and negative symptom dimensions.  
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remained after adjusting for depressive symptoms. 
Psychotic symptoms reported by adolescents/adults in general pop-
ulation exist on a continuum with that in schizophrenia (van Os et al., 
2009). Longitudinal studies suggest that psychotic symptoms in child-
hood/adolescence are associated with increased risks for psychosis 
(Poulton et al., 2000; Zammit et al., 2013) and depression (Rossler et al., 
2011) subsequently in adulthood. Therefore, these symptoms are 
considered as important risk markers for a wide range of psychiatric 
disorders (Kelleher et al., 2012b). Previous studies have reported an 
association of CRP with negative symptoms (Boozalis et al., 2017), 
general psychopathology (Fan et al., 2007) and cognitive dysfunction 
(Dickerson et al., 2007; Johnsen et al., 2016) in patients with psychosis. 
Our findings suggest that inflammation is also associated with 
sub-clinical manifestations of psychosis in general population. 
Association of inflammation with symptoms that commonly occur in 
different psychiatric disorders may be one explanation for the reported 
trans-diagnostic effect of inflammation. Anhedonia and auditory hallu-
cinations occur in a number of psychiatric disorders including schizo-
phrenia and depression (APA, 2013). Inflammation has been implicated 
in both of these disorders (Dantzer et al., 2008; Khandaker et al., 2015; 
Miller et al., 2009, 2011). Inflammation is associated with anhedonia 
like behavior in animals and humans, which could be mediated by its 
effect on striatal dopamine synthesis/release (Capuron et al., 2012) and 
reward perception (Eisenberger et al., 2010). In non-human primates, 
chronic, low-dose peripheral interferon administration reduces striatal 
dopamine release in association with anhedonia-like behavior (Felger 
et al., 2013). In healthy volunteers, inflammation induces hedonic al-
terations (decreased preference for reward and increased avoidance of 
punishment) (Harrison et al., 2016), which resemble anhedonia. In 
depressed patients, increased plasma CRP levels are associated with 
anhedonia and psychomotor retardation (Felger et al., 2016). 
Inflammation could also influence reward perception by affecting 
glutamatergic neurotransmission. Inflammatory cytokines activate 
indoleamine 2,3 dioxygenase (IDO), an enzyme that breaks down 
tryptophan along the kynurenine pathway, leading to increased levels of 
kynurenic acid and quinolinic acid (Haroon et al., 2012). Kynurenic acid 
is the only naturally occurring N-methyl D-Aspartate receptor (NMDAR) 
antagonist in the human CNS (Schwarcz and Pellicciari, 2002). 
Table 2 
Odds ratio for positive symptoms of psychosis around age 17 Years for serum CRP levels around age 16 Years in the ALSPAC birth cohort.  
Outcome CRP Level Sample Symptom Present, 
No. (%) 
Odds Ratio (95% CI) for Positive Symptoms 
Unadjusted Adjusted for age at outcome, sex, BMI, father’s 
occupation, ethnicity, and total SMFQ scorea 
Additional adjustment for smoking, 
alcohol, cannabis and other drug useb 
Auditory Hallucination  
Low (<1 mg/ 
L) 
1912 63 (3.3) 1 [Reference] 1 [Reference] 1 [Reference]  
Medium (1–3 
mg/L) 
351 19 (5.4) 1.68 
(1.00–2.84) 
1.51 (0.81–2.81) 1.23 (0.62–2.44)  
High (>3 mg/ 
L) 
158 12 (7.6) 2.41 
(1.27–4.57) 
2.14 (1.03–4.47) 2.22 (1.04–4.76) 
Visual Hallucination  
Low (<1 mg/ 
L) 
1912 78 (4.1) 1 [Reference] 1 [Reference] 1 [Reference]  
Medium (1–3 
mg/L) 
351 13 (3.7) 0.90 
(0.50–1.64) 
0.65 (0.32–1.36) 0.66 (0.31–1.42)  
High (>3 mg/ 
L) 
158 11 (7.0) 1.76 
(0.92–3.38) 
1.44 (0.67–3.10) 0.92 (0.36–2.33) 
Paranoid Beliefs of Being Followed/Spied On  
Low (<1 mg/ 
L) 
1912 83 (4.3) 1 [Reference] 1 [Reference] 1 [Reference]  
Medium (1–3 
mg/L) 
351 17 (4.8) 1.12 
(0.65–1.91) 
1.22 (0.66–2.24) 1.32 (0.71–2.84)  
High (>3 mg/ 
L) 
158 12 (7.6) 1.81 
(0.97–3.40) 
2.07 (1.03–4.19) 1.85 (0.85–4.01) 
Any Hallucinations  
Low (<1 mg/ 
L) 
1912 116 (6.1) 1 [Reference] 1 [Reference] 1 [Reference]  
Medium (1–3 
mg/L) 
351 24 (6.8) 1.13 
(0.72–1.79) 
0.96 (0.56–1.65) 0.84 (0.46–1.52)  
High (>3 mg/ 
L) 
158 18 (11.4) 2.00 
(1.17–3.36) 
1.78 (0.97–3.27) 1.43 (0.73–2.82) 
Any Delusions  
Low (<1 mg/ 
L) 
1912 162 (8.5) 1 [Reference] 1 [Reference] 1 [Reference]  
Medium (1–3 
mg/L) 
351 25 (7.1) 0.82 
(0.53–1.28) 
0.82 (0.49–1.37) 0.87 (0.52–1.46)  
High (>3 mg/ 
L) 
158 20 (12.7) 1.56 
(0.95–2.57) 
1.37 (0.75–2.51) 1.30 (0.70–2.46) 
Any Thought Interferences  
Low (<1 mg/ 
L) 
1912 27 (1.4) 1 [Reference] 1 [Reference] 1 [Reference]  
Medium (1–3 
mg/L) 
351 4 (1.1) 0.80 
(0.28–2.31) 
0.95 (0.31–2.99) 0.76 (0.21–2.84)  
High (>3 mg/ 
L) 
158 1 (0.6) 0.44 
(0.06–3.29) 
0.52 (0.06–4.02) 0.48 (0.06–3.80)  
a Short Mood and Feelings Questionnaire (SMFQ) was completed by participants at the time of questionnaire assessment of psychotic symptoms. BMI was assessed 
around blood collection for CRP assay. 
b Number of cigarettes smoked per day, frequency of alcohol use, amount of cannabis used in past three months, and use of other drugs since 15th birthday were 
recorded using a questionnaire at the time of assessment of psychotic symptoms. Other drugs included inhaling/sniffing of gas, solvent, aerosol, glue or poppers (alkyl 
nitrites); use of stimulants (amphetamine, MDMA, cocaine or crack cocaine), hallucinogens (LSD, magic mushroom); heroin, ketamine, and anabolic steroids. 
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Concentrations of kynurenic acid are higher in the CSF and brain tissue 
of schizophrenia patients compared with healthy controls (Schwarcz 
et al., 2001). Injection of ketamine (an NMDAR antagonist) in healthy 
volunteers has been reported to produce phenomena resembling nega-
tive symptoms (Pomarol-Clotet et al., 2006). 
Strengths of the work include use of a longitudinal, general 
population-based sample, data on positive and negative symptoms, and 
a number of relevant confounders including depressive symptoms and 
substance misuse. We used two different analytic approaches, regression 
and factor analysis, which yielded consistent results. A key limitation of 
the study is the use of self-reported symptoms, as lack of scrutiny from 
an interviewer and misinterpretation of questions by participants could 
contribute to measurement error especially for negative symptoms. To 
minimize such error, we recoded individual positive and negative 
symptoms into binary variables to ensure that only symptoms reported 
as definitely present or often/always present were coded as ‘yes’. The 
prevalence of these symptoms, such as hallucinations in our sample, 
were not overly high, suggesting that participants did not endorse 
symptoms wholesale. Majority of participants had attended a face-to- 
face interview for psychotic symptoms previously at age 12 with a 
trained assessor (Zammit et al., 2013), so they would have been familiar 
with what the questionnaires were trying to establish. 
The prevalence of any positive symptom in this adolescent sample 
(13.3%) is comparable to that in other studies. According to a systematic 
review of population-based studies, the median prevalence of 
questionnaire-assessed positive symptoms in childhood/adolescence is 
around 9% (prevalence range from 4.7 to 35.3%) (Kelleher et al., 
2012a). Studies of psychotic symptoms particularly those based on 
general population samples have often focused only on positive symp-
toms (Kelleher et al., 2012a), so this is one of the few studies of this kind 
to include negative symptoms. High prevalence is unlikely to explain the 
association of auditory hallucinations with CRP. CRP was not associated 
with visual hallucinations or paranoid ideation, which were more 
common than auditory hallucinations. 
The length of follow-up for this longitudinal study was approxi-
mately one year; CRP was measured around age 16 and psychotic 
symptoms were assessed around age 17. However, the questionnaire 
elicited occurrence of positive symptoms anytime since 15th birthday, 
so the possibility that some participants might have experienced these 
symptoms before CRP measurement cannot be ruled out. It is note-
worthy that evidence for association between CRP and auditory hallu-
cinations persisted even after excluding participants who had reported 
any psychotic symptoms previously at age 12. 
Other limitations include use of one off measurement for CRP and 
lack of data on other inflammatory markers. However, CRP is a reliable 
marker of low-grade inflammation that has been used extensively in the 
literature. Anhedonia, asociality and alogia were measured using a 
single question, so in future studies should use more detailed assess-
ments for these symptoms. Number of cases for some of the rare 
symptoms, such as thought interference, were relatively small, so in 
future studies with larger samples are required. 
Mechanisms for how inflammation cause auditory hallucinations 
require further investigation. Childhood abuse/maltreatment is associ-
ated with increased risk of auditory hallucinations, psychotic disorders 
(Sheffield et al., 2013) and with increased concentrations inflammatory 
markers (Baumeister et al., 2016). Whether low-grade inflammation 
mediates the relationship between childhood maltreatment and audi-
tory hallucinations in adolescence or adult psychotic disorders is an 
important hypothesis that future studies should address. 
Associations of CRP with positive and negative symptom factor 
scores were similar. However, composite scores can sometimes mask 
heterogeneity of association at individual symptom level in the case of 
heterogeneous syndromes like psychosis or depression, as evident from 
Table 3 
Association between serum CRP level around age 16 Years and negative symp-
toms of psychosis around age 17 Years in the ALSPAC birth cohort.  
Symptom 
Subtype 
Adjustment for 
Confounders 
Sample OR (95% CI)d P- 
Value 
Anhedonia Unadjusted analysis 2419 1.13 
(1.04–1.23) 
0.003  
Adjusted for age at 
outcome, sex, BMI, 
father’s occupation, and 
ethnicity 
2078 1.15 
(1.05–1.26) 
0.001  
Adjusted for total SMFQ 
scorea 
2371 1.14 
(1.03–1.25) 
0.007  
Adjusted for substance 
misuseb 
2293 1.11 
(1.02–1.22) 
0.022  
Fully adjustedc 1944 1.13 
(1.02–1.26) 
0.023 
Asociality Unadjusted analysis 2419 1.13 
(1.02–1.25) 
0.020  
Adjusted for age at 
outcome, sex, BMI, 
father’s occupation, and 
ethnicity 
2078 1.13 
(1.02–1.26) 
0.022  
Adjusted for total SMFQ 
scorea 
2371 1.11 
(0.98–1.26) 
0.084  
Adjusted for substance 
misuseb 
2293 1.16 
(1.04–1.29) 
0.008  
Fully adjustedc 1944 1.14 
(1.00–1.31) 
0.064 
Alogia Unadjusted analysis 2419 1.08 
(1.00–1.18) 
0.067  
Adjusted for age at 
outcome, sex, BMI, 
father’s occupation, and 
ethnicity 
2078 1.09 
(1.01–1.19) 
0.036  
Adjusted for total SMFQ 
scorea 
2371 1.07 
(0.97–1.17) 
0.169  
Adjusted for substance 
misuseb 
2293 1.06 
(0.96–1.17) 
0.236  
Fully adjustedc 1944 1.05 
(0.94–1.17) 
0.365 
Symptom 
Subtype 
Adjustment for 
Confounders 
Sample Regression Co- 
efficient (SE)e 
P- 
Value 
Avolition Unadjusted analysis 2419 0.040 (0.023) 0.087  
Adjusted for age at 
outcome, sex, BMI, 
father’s occupation, and 
ethnicity 
2078 0.047 (0.23) 0.047  
Adjusted for total SMFQ 
scorea 
2371 0.024 (0.020) 0.229  
Adjusted for substance 
misuseb 
2293 0.038 (0.025) 0.122  
Fully adjustedc 1944 0.027 (0.022) 0.209 
Blunted 
Affect 
Unadjusted analysis 2419 0.004 (0.009) 0.693  
Adjusted for age at 
outcome, sex, BMI, 
father’s occupation, and 
ethnicity 
2078 0.002 (0.009) 0.820  
Adjusted for total SMFQ 
scorea 
2371 − 0.002 (0.008) 0.768  
Adjusted for substance 
misuseb 
2293 − 0.003 (0.010) 0.797  
Fully adjustedc 1944 − 0.009 (0.009) 0.310  
a Short Mood and Feelings Questionnaire (SMFQ) was completed by partici-
pants at the time of questionnaire assessment of negative symptoms. 
b Number of cigarettes smoked per day, frequency of alcohol use, amount of 
cannabis used in past three months, and use of other drugs since 15th birthday 
were recorded using a questionnaire at the time of assessment of psychotic 
symptoms. Other drugs included inhaling/sniffing of gas, solvent, aerosol, glue 
or poppers (alkyl nitrites); use of stimulants (amphetamine, MDMA, cocaine or 
crack cocaine), hallucinogens (LSD, magic mushroom); heroin, ketamine, and 
anabolic steroids. 
c Adjusted for all co-variates, i.e. age at outcome, sex, BMI, father’s occupa-
tion, ethnicity, total SMFQ score, smoking, alcohol, cannabis and other drug use. 
d Logistic regression was used to calculate OR and 95% confidence intervals 
for each symptom per SD increase in serum CRP level. 
e Linear regression was used to calculate regression coefficient and standard 
error for each symptom per SD increase in serum CRP level. 
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our data. A symptom-based approach may help to provide a better un-
derstanding of the role of inflammation in psychiatric disorders. For 
instance, our findings suggest that association of CRP with symptoms 
commonly shared between mood and psychotic disorders, such as 
auditory hallucinations and anhedonia, could be one explanation for the 
apparent trans-diagnostic effect of inflammation. Using a symptom- 
based approach, emerging evidence provides some clarity regarding 
potential role of inflammation in depression. Findings from the Dutch 
NESDA cohort (Duivis et al., 2013), UK ALSPAC cohort (Chu et al., 
2019), US cohorts (Jokela et al., 2016), and from clinical sample 
(Kohler-Forsberg et al., 2017) suggest that inflammation is mainly 
associated with somatic/neurovegetative symptoms (e.g., fatigue, sleep 
disturbance) rather than psychological symptoms of depression. Such 
evidence could help to inform new and more personalized approaches to 
treatment and prevention of psychiatric disorders. 
A clearer understanding of inflammation-related phenotypes could 
inform clinical trials of anti-inflammatory drugs for depression and 
schizophrenia. Elevated inflammatory markers at baseline predict poor 
antipsychotic response in first episode psychosis (Mondelli et al., 2015). 
Anti-inflammatory drugs may be helpful for some, but not all, patients 
with depression, especially those with evidence of inflammation (Kap-
pelmann et al., 2018; Raison et al., 2013). Therefore, a more person-
alized/stratified approach to sample selection in RCTs is required. 
Patients with psychosis who show evidence of inflammation and 
inflammation related symptoms, such as anhedonia and auditory hal-
lucinations, may be better candidates for RCTs of anti-inflammatory 
drugs. 
In summary, we provide evidence that previously reported associa-
tion of inflammation with psychotic disorders extend to sub-clinical 
manifestations of psychotic symptoms in young people. Our findings 
also suggest that association of CRP with symptoms commonly shared 
between mood and psychotic disorders, such as auditory hallucinations 
and anhedonia, could be one explanation for the apparent trans- 
diagnostic effect of inflammation. Replication of these findings in 
other samples particularly in patients with psychosis are required. 
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